Please Wait a Moment
X

Articles

19Jul

FDA Releases ZIKV Guidance and Grifols ZIKV Assay Licensed- 1st Update

19 Jul, 2018 | Return|

This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.

Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications

Related

Renewed licenses now available on the website

As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....

Read More >

CTS conversion to the Ortho VERSEIA Integrated Processor (VIP) in January 2021

After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...

Read More >

Update on CTS Implementation of the Grifols Procleix Ultrio Elite Assay

In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...

Read More >

Exhibiting at AABB Annual Meeting- Booth 732

We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...

Read More >

FDA Releases Zika Virus (ZIKV) Guidance and Grifols ZIKV Assay Licensed

On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...

Read More >

Seasonal Monitoring for WNV to begin June 1, 2020

Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...

Read More >